1-氯-4-异喹啉羧酸甲酯 | 37497-86-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 1-氯-4-异喹啉羧酸甲酯
• 英文名称: 1-chloro-isoquinoline-4-carboxylic acid methyl ester
• 英文别名: methyl 1-chloroisoqiunoline-4-carboxylate；methyl 1-chloroisoquinoline-4-carboxylate；1-Chlor-4-carbomethoxyisochinolin
• CAS: 37497-86-2
• 化学式: C₁₁H₈ClNO₂
• mdl: MFCD00140353
• 分子量: 221.643
• InChiKey: YTJDBMFLRYQTPT-UHFFFAOYSA-N

物化性质

• 沸点：
  344.9±22.0 °C(Predicted)
• 密度：
  1.330±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-氯-4-异喹啉羧酸甲酯 在 甲醇 、 草酰氯 、 水 、 氧气 、 sodium hexamethyldisilazane 、 sodium hydroxide 、 三甲基硅烷化重氮甲烷 作用下， 以 四氢呋喃 、 氯仿 、 乙腈 为溶剂， 生成 tert-butyl 4-{[4-(2-methoxy-2-oxoethyl)isoquinolin-1-yl]carbonyl}benzoate
  参考文献：
  名称：

  Isoquinoline derivatives as potent CRTH2 receptor antagonists: Synthesis and SAR

  摘要：

  Synthesis and structure-activity relationship of a novel series of isoquinoline CRTH2 receptor antagonists are described. One of the most potent compounds, TASP0376377 (6m), showed not only potent binding affinity (IC50 = 19 nM) but also excellent functional antagonist activity (IC50 = 13 nM). TASP0376377 was tested for its ability of a chemotaxis assay to show the effectiveness (IC50 = 23 nM), which was in good agreement with the CRTH2 antagonist potency. Furthermore, TASP0376377 showed sufficient selectivity for binding to CRTH2 over the DP1 prostanoid receptor (IC50 > 1 mu M) and COX-1 and COX-2 enzymes (IC50 > 10 mu M). (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.009
• 作为产物：
  描述：

  1-氧代-1,2-二氢-4-异喹啉羧酸甲酯 以 氯仿 、 三氯氧磷 为溶剂， 生成 1-氯-4-异喹啉羧酸甲酯
  参考文献：
  名称：

  Bicyclic and tricyclic heteroaromatic compounds

  摘要：

  本发明涉及化合物的公式：以及其药学上可接受的盐，其中W、Q、X、X1、Y和Z的定义如本文所述。这些化合物与GABAA受体的苯二氮平位点高度选择性和/或高亲和力结合，因此在中枢神经系统（CNS）疾病的治疗和作为探针用于组织样本中GABAA受体的定位中有用。本发明还涉及在制备这些化合物过程中有用的中间体。

  公开号：

  US06511987B1

文献信息

• [EN] PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE EN TANT QUE BLOQUANTS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2014068988A1

  公开（公告）日：2014-05-08

  The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及吡唑并吡啶衍生物，这些衍生物具有阻断TTX-S型电压门控钠通道的活性，并且在治疗或预防涉及电压门控钠通道的疾病和障碍中是有用的。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病中的用途。
• Amine Compounds
  申请人：Ohmori Yutaka

  公开号：US20080200535A1

  公开（公告）日：2008-08-21

  There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.

  提供了一种化合物，具有抑制免疫反应并减少不良药物反应的活性，该化合物在化疗中用于预防或治疗各种自身免疫性疾病，包括系统性红斑狼疮、慢性类风湿关节炎、I型糖尿病、炎症性肠病、胆汁性肝硬化、葡萄膜炎、多发性硬化或其他疾病，慢性炎症性疾病，癌症，淋巴瘤或白血病，器官或组织移植的抗性或对移植的排斥。提供了具有S1P1/Edg1受体激动剂作用的新型胺类化合物，可能是这些化合物的立体异构体或消旋体，或这些化合物、立体异构体或消旋体的药理学上可接受的盐、水合物或溶剂合物，或这些化合物、立体异构体、消旋体、盐、水合物或溶剂的前药。
• Isoquinoline Derivatives as Potent, Selective, and Orally Active CRTH2 Antagonists
  作者：Rie Nishikawa-Shimono、Yoshinori Sekiguchi、Madoka Kawamura、Daisuke Wakasugi、Masahumi Kawanishi、Kazuhito Watanabe、Yumiko Asakura、Akiko Takaoka、Tetsuo Takayama

  DOI：10.1248/cpb.c13-00980

  日期：——

  relationship of a novel series of isoquinoline CRTH2 antagonists bearing a methylene linker between the isoquinoline and benzamide moieties were described. Optimization focusing on the substituents of the benzamide portion in the right hand part of the molecule led to the identification of TASP0412098 (9l), which is a potent, selective CRTH2 antagonist (binding affinity: IC50=2.1 nM, functional activity:

  描述了一系列新的异喹啉CRTH2拮抗剂的合成及其构效关系，该拮抗剂在异喹啉和苯甲酰胺部分之​​间带有亚甲基接头。着眼于分子右手部分的苯甲酰胺部分取代基的优化导致鉴定出TASP0412098（9l），这是一种有效的选择性CRTH2拮抗剂（结合亲和力：IC50 = 2.1 nM，功能活性：IC50 = 12 nM）。在小鼠和豚鼠中口服生物利用的化合物9l在豚鼠的支气管哮喘模型中口服给药后显示出体内功效。
• ISOQUINOLINE DERIVATIVE
  申请人：Takayama Tetsuo

  公开号：US20130096310A1

  公开（公告）日：2013-04-18

  A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a pharmaceutical.

  由化学式(I)表示的化合物或其药用盐具有抑制CRTH2的作用，因此可用作药物。
• Bicyclic and tricyclic hetroaromatic compounds
  申请人：Neurogen Corporation, A Corporation of the State of Delaware

  公开号：US20030181455A1

  公开（公告）日：2003-09-25

  Disclosed are compounds of the formula: 1 and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X 1 , Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABA A receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes for the localization of GABA A receptors in tissue samples. Also disclosed are intermediates useful in the preparation of these compounds.

  本发明涉及以下式子的化合物及其药学上可接受的盐，其中W、Q、X、X1、Y和Z的定义如下。这些化合物与GABAA受体的苯二氮平位点具有高选择性和/或高亲和力，因此可用于治疗中枢神经系统（CNS）疾病，并作为探针用于定位组织样本中的GABAA受体。本发明还涉及用于制备这些化合物的中间体。